SCYNEXIS INC. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. SCYNEXIS, Inc. is a clinical-stage biotech company focused on severe rare diseases. Key assets include SCY-770, an AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD) acquired from Poxel SA, and SCY-247, an antifungal candidate. The company also holds rights to the licensed antifungal BREXAFEMME.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $257,000 |
| Net Loss | $(21,299,000) | $(5,391,000) |
| Operating Expenses | $16,939,000 | $8,867,000 |
| Cash & Investments | $72,400,000 | $56,300,000 |
| Warrant Liabilities | $18,862,000 | $2,225,000 |
| Accumulated Deficit | $(406,443,000) | $(381,926,000) |
Liquidity: Cash and cash equivalents were $36.7 million, with total investments of $35.7 million. Management believes resources are sufficient for at least 12 months.
Material Changes vs. Prior Period
- Revenue: Dropped to zero from $257,000 in Q1 2025, as no license agreement revenue was recognized in the current quarter.
- Net Loss: Increased significantly to $21.3 million from $5.4 million. This was driven by a $5.2 million loss on warrant liability fair value adjustments and an $8.0 million upfront payment for the SCY-770 acquisition.
- R&D Expenses: Rose 140% to $12.4 million, primarily due to the $8.0 million in-process research and development (IPR&D) expense for the Poxel asset purchase.
- Capital Structure: The company completed a March 2026 Private Placement, raising $40.0 million in gross proceeds (with $24.0 million received by quarter-end). This resulted in a significant increase in warrant liabilities and outstanding shares.
Outlook, Risks, and Unusual Items
- Private Placement: The March 2026 offering included common stock, pre-funded warrants, and common warrants. The common warrants were classified as liabilities due to insufficient authorized shares, creating volatility in net loss based on stock price fluctuations.
- Asset Acquisition: The $8.0 million upfront payment for SCY-770 was expensed immediately. Future milestones include up to $8.0 million in development payments and $180.0 million in commercial milestones.
- Nasdaq Compliance: The company received an extension until June 15, 2026, to regain compliance with the $1.00 minimum bid price rule. Failure to comply may result in delisting or a reverse stock split.
- Development Timeline: SCY-770 Phase 1 confirmatory study is expected in Q3 2026, with Phase 2 initiation in Q4 2026. SCY-247 IV Phase 1 data is expected in Q3 2026.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of stock price movements on the $18.9 million warrant liability and its effect on future net loss.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by June 15, 2026, to avoid delisting.
- Capital Runway: Confirm the burn rate against the $72.4 million cash position to validate the 12-month liquidity assertion.
- Private Placement Terms: Review the conditions for the remaining $16.0 million in proceeds and the stockholder approval required for warrant exercisability.
- SCY-770 Milestones: Track the initiation of the Phase 2 trial to trigger the $2.0 million development milestone payment.